Moreover, we identified LINC00261 as a tumor suppressor with clinical significance that functions by sponging miR-222-3p to activate the HIPK2/ERK pathway and sequestering IGF2BP1 to attenuate the c-myc-mediated glycolytic process, which, in turn, inhibited the proliferation of pancreatic cancer cells. Here, MYC is linked to familial pancreatic carcinoma.